McKesson Corporation (MCK)
Official siteHEALTHCARE • MEDICAL DISTRIBUTION • NYSE
Market Cap: $127.33B
Last updated: Nov 17, 2026 at 11:06 AM ET
McKesson Corporation (MCK) Earnings: Report Dates and Results
McKesson (MCK) is expected to report earnings on Feb 2, 2027. In the quarter ended Sep 30, 2026, McKesson reported EPS of $11.68, above the $10.69 estimate. It beat the EPS estimate in each of the last 10 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
MCK has an expected report date of Feb 2, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 17.2% above the $9.34 reported for the quarter ended Dec 31, 2025.
MCK Earnings Call
The latest MCK earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, MCK beat 34, missed 5 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $110.96B, up 7.6% from $103.15B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $11.68 | $10.69 | $10.53 - $11.26 | +9.26% | Beat | +18.5% | 15 | 1 up, 0 down | Nov 4, 2026 | $110.96B |
| Jun 30, 2026 | $9.93 | $9.44 | $9.25 - $9.89 | +5.19% | Beat | +20.2% | 15 | 0 up, 4 down | Aug 5, 2026 | $105.38B |
| Mar 31, 2026 | $11.69 | $11.57 | $11.45 - $11.67 | +1.04% | Beat | +15.5% | 16 | 1 up, 0 down | May 7, 2026 | $96.30B |
| Dec 31, 2025 | $9.34 | $9.27 | $9.05 - $10.01 | +0.76% | Beat | +16.3% | 15 | 2 up, 2 down | Feb 4, 2026 | $106.16B |
| Sep 30, 2025 | $9.86 | $8.92 | $8.53 - $9.49 | +10.54% | Beat | +39.5% | 14 | 2 up, 3 down | Nov 5, 2025 | $103.15B |
| Jun 30, 2025 | $8.26 | $8.15 | $7.78 - $8.49 | +1.35% | Beat | +4.8% | 12 | 0 up, 5 down | Aug 6, 2025 | $97.83B |
| Mar 31, 2025 | $10.12 | $9.83 | $9.67 - $9.96 | +2.95% | Beat | +63.8% | 14 | 3 up, 1 down | May 8, 2025 | $90.82B |
| Dec 31, 2024 | $8.03 | $7.99 | $7.82 - $8.24 | +0.50% | Beat | +3.7% | 14 | 0 up, 7 down | Feb 5, 2025 | $95.29B |
| Sep 30, 2024 | $7.07 | $6.87 | $6.76 - $7.03 | +2.91% | Beat | +13.5% | 15 | 1 up, 1 down | Nov 6, 2024 | $93.65B |
| Jun 30, 2024 | $7.88 | $7.21 | $7.10 - $7.38 | +9.29% | Beat | +8.4% | 15 | 4 up, 0 down | Aug 7, 2024 | $79.28B |
| Mar 31, 2024 | $6.18 | $6.36 | $6.20 - $6.68 | -2.83% | Miss | -14.0% | 15 | 2 up, 1 down | May 7, 2024 | $76.36B |
| Dec 31, 2023 | $7.74 | $7.05 | $6.85 - $7.29 | +9.79% | Beat | +12.2% | 14 | 6 up, 0 down | Feb 7, 2024 | $80.90B |
| Sep 30, 2023 | $6.23 | $6.15 | $5.96 - $6.26 | +1.30% | Beat | +2.8% | 12 | 1 up, 1 down | Nov 1, 2023 | $77.22B |
| Jun 30, 2023 | $7.27 | $5.87 | $5.73 - $6.05 | +23.85% | Beat | +24.7% | 13 | 1 up, 1 down | Aug 2, 2023 | $74.48B |
| Mar 31, 2023 | $7.19 | $7.12 | $7.05 - $7.30 | +0.98% | Beat | +23.3% | 14 | 1 up, 0 down | May 8, 2023 | $68.91B |
| Dec 31, 2022 | $6.90 | $6.36 | $6.24 - $6.51 | +8.49% | Beat | +12.2% | 12 | 2 up, 1 down | Feb 1, 2023 | $70.49B |
| Sep 30, 2022 | $6.06 | $6.10 | $5.89 - $6.45 | -0.66% | Miss | -1.5% | 12 | 4 up, 0 down | Nov 1, 2022 | $70.16B |
| Jun 30, 2022 | $5.83 | $5.30 | $5.18 - $5.35 | +10.00% | Beat | +4.9% | 12 | 4 up, 0 down | Aug 3, 2022 | $67.15B |
| Mar 31, 2022 | $5.83 | $6.04 | $5.83 - $6.35 | -3.48% | Miss | +15.4% | 12 | 1 up, 1 down | May 5, 2022 | $66.10B |
| Dec 31, 2021 | $6.15 | $5.42 | $5.02 - $5.89 | +13.47% | Beat | +33.7% | 12 | 10 up, 0 down | Feb 2, 2022 | $68.61B |
| Sep 30, 2021 | $6.15 | $4.66 | $4.50 - $5.08 | +31.97% | Beat | +28.1% | 12 | N/A | Nov 1, 2021 | $66.58B |
| Jun 30, 2021 | $5.56 | $4.14 | $3.28 - $4.43 | +34.30% | Beat | +100.7% | 12 | N/A | Aug 4, 2021 | $62.67B |
| Mar 31, 2021 | $5.05 | $5.05 | $4.93 - $5.19 | 0.00% | In line | +18.3% | 14 | N/A | May 6, 2021 | $59.14B |
| Dec 31, 2020 | $4.60 | $4.13 | $3.98 - $4.28 | +11.38% | Beat | +20.7% | 16 | N/A | Feb 2, 2021 | $62.60B |
| Sep 30, 2020 | $4.80 | $3.88 | $3.74 - $4.09 | +23.71% | Beat | +33.3% | 15 | N/A | Nov 3, 2020 | $60.81B |
| Jun 30, 2020 | $2.77 | $2.39 | $1.96 - $2.50 | +15.90% | Beat | -16.3% | 14 | N/A | Aug 3, 2020 | $55.68B |
| Mar 31, 2020 | $4.27 | $4.10 | $3.87 - $4.20 | +4.15% | Beat | +15.7% | 15 | N/A | May 20, 2020 | $58.53B |
| Dec 31, 2019 | $3.81 | $3.49 | $3.47 - $3.78 | +9.17% | Beat | +12.1% | 10 | N/A | Feb 4, 2020 | $59.17B |
| Sep 30, 2019 | $3.60 | $3.59 | $3.50 - $3.69 | +0.28% | Beat | 0.0% | 15 | N/A | Oct 30, 2019 | $57.62B |
| Jun 30, 2019 | $3.31 | $3.01 | $2.85 - $3.14 | +9.97% | Beat | +14.1% | 14 | N/A | Jul 31, 2019 | $55.73B |
| Mar 31, 2019 | $3.69 | $3.66 | $3.60 - $3.71 | +0.82% | Beat | +5.7% | 15 | N/A | May 8, 2019 | $52.43B |
| Dec 31, 2018 | $3.40 | $3.16 | $3.00 - $3.30 | +7.59% | Beat | -0.3% | 16 | N/A | Jan 31, 2019 | $56.21B |
| Sep 30, 2018 | $3.60 | $3.28 | $3.13 - $3.53 | +9.76% | Beat | +9.8% | 16 | N/A | Oct 25, 2018 | $53.08B |
| Jun 30, 2018 | $2.90 | $2.89 | $2.73 - $2.95 | +0.35% | Beat | +17.9% | 15 | N/A | Jul 26, 2018 | $52.61B |
| Mar 31, 2018 | $3.49 | $3.56 | $3.35 - $3.66 | -1.97% | Miss | +2.0% | 16 | N/A | May 24, 2018 | $51.63B |
| Dec 31, 2017 | $3.41 | $2.95 | $2.82 - $3.15 | +15.59% | Beat | +11.8% | 15 | N/A | Feb 1, 2018 | $53.62B |
| Sep 30, 2017 | $3.28 | $2.79 | $2.59 - $2.90 | +17.56% | Beat | +11.6% | 12 | N/A | Oct 26, 2017 | $52.06B |
| Jun 30, 2017 | $2.46 | $2.83 | $2.72 - $2.89 | -13.07% | Miss | -29.7% | 16 | N/A | Jul 27, 2017 | $51.05B |
| Mar 31, 2017 | $3.42 | $3.01 | $2.91 - $3.10 | +13.62% | Beat | +7.9% | 14 | N/A | May 18, 2017 | $48.71B |
| Dec 31, 2016 | $3.05 | $2.91 | N/A | +4.81% | Beat | -4.1% | N/A | N/A | Jan 25, 2017 | $50.13B |
Annual EPS
EPS for the fiscal year ended Mar 31, 2026 was $39.15, up 18.3% from the year before. It was $12.91 for the year ended Mar 31, 2017, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Mar 31, 2026 | $39.15 | +18.3% |
| Mar 31, 2025 | $33.10 | +20.7% |
| Mar 31, 2024 | $27.42 | +5.5% |
| Mar 31, 2023 | $25.98 | +9.7% |
| Mar 31, 2022 | $23.69 | +37.6% |
| Mar 31, 2021 | $17.22 | +14.9% |
| Mar 31, 2020 | $14.99 | +10.3% |
| Mar 31, 2019 | $13.59 | +7.5% |
| Mar 31, 2018 | $12.64 | -2.1% |
| Mar 31, 2017 | $12.91 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 6,400 words across 15 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 6,368 | 15 | |
| 2026Q2 | Jun 30, 2026 | 8,233 | 17 | |
| 2026Q1 | Mar 31, 2026 | 7,629 | 15 | |
| 2025Q4 | Dec 31, 2025 | 8,812 | 13 | |
| 2025Q3 | Sep 30, 2025 | 8,386 | 16 | |
| 2025Q2 | Jun 30, 2025 | 9,332 | 17 | |
| 2025Q1 | Mar 31, 2025 | 8,155 | 14 | |
| 2024Q4 | Dec 31, 2024 | 8,031 | 15 |
2026Q3 Earnings Call
Opening remarks
Jeni Dominguez VP of Investor Relations Thank you, operator. Good afternoon, and welcome, everyone, to McKesson Corporation's Third Quarter Fiscal 2026 Earnings Call. Today, I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vitalone, our Chief Financial Officer. Brian will speak first, followed by Britt, and then we'll move to a question and answer session. Today's discussion will include forward-looking statements such as forecasts about McKesson Corporation's operations and future results. Please refer to the cautionary statements in today's earnings release and presentation slides available on our website at investors.mckesson.com and to the Risk Factors section of our most recent annual and periodic SEC filings for additional information concerning risk factors that could cause our actual results to materially differ from those in our forward-looking statements. Information about non-GAAP financial measures that we will discuss during this webcast, including a reconciliation of those measures to GAAP results, can be found in today's earnings release and presentation slides. The presentation slides also include a summary of our results for the quarter and guidance assumptions. With that, let me turn it over to Brian.
Brian Tyler Chief Executive Officer Thank you, Jeni. Good afternoon, everyone. Appreciate you joining McKesson Corporation's fiscal third quarter earnings call. Today's results once again demonstrate the strength and durability of our business. Revenue and adjusted EPS grew double digits driven by continued momentum across oncology, biopharma services, and North American distribution. The consistency of this performance gives us the confidence to raise full-year EPS guidance to a range of $38.80 to $39.20, which reflects 17 to 19% year-over-year growth. I want to thank team McKesson for their unwavering commitment to excellence and innovation, driving tangible impacts every day for our stakeholders and keeping patients at the center of everything that we do. Today, my remarks will focus on the continued progress of our company priorities and the momentum we are driving across the organization and, of course, recognizing the dedication and engagement across team McKesson. Then, as is customary, I'll hand it over to Britt for a more detailed review of the financials. So let me start where I usually do with our people and our culture. We aspire to be the best place to work in health care, and supporting our employees' growth and success remains a top priority. Our employee resource groups play a critical role in strengthening connections and reinforcing our culture of care and belonging. These employee-led networks empower colleagues to come together to advance the business and to build an environment where everyone can thrive. This year, we're pleased to see membership of more than 30%. Participation in these groups results in increased employee engagement, improved retention, and better business outcomes.
Frequently Asked Questions About MCK
When is McKesson's next earnings date?
McKesson's next earnings report is expected for Feb 2, 2027.
Did MCK beat earnings estimates last quarter?
Yes. McKesson reported EPS of $11.68 for the quarter ended Sep 30, 2026, above the $10.69 estimate, a 9.26% surprise.
What EPS do analysts expect from MCK next quarter?
The consensus EPS estimate for McKesson for the quarter ending Dec 31, 2026 is $10.95 from 10 analysts, with estimates from $10.49 to $11.71.
How often does MCK beat earnings estimates?
McKesson beat the EPS estimate in each of the last 10 quarters, with an average surprise of +4.38%.
MCK pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts